CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
Systemic administration of RB 101, a complete inhibitor of enkephalin catabolism, has been reported to induce antidepressant-like responses in mice which were potentiated by an ineffective dose of a CCK-B antagonist. The aim of this study was to investigate the neuroanatomical substrate involved in the facilitatory effects induced by CCK-B antagonists on RB 101 behavioural responses. Thus, the CCK-B antagonist PD-134,308 was locally administered into different brain structures (anterior nucleus accumbens, central amygdala and caudate nucleus) and its effects on the antidepressant-like response induced by systemic administration of RB 101 were evaluated in the conditioned suppression of motility (CSM) test in rats. RB 101 administered alone by the IV route decreased the CSM in rats, as previously obtained in mice. Systemic administration of a non effective dose of PD-134,308 facilitated the antidepressant-like effect induced by RB 101. Local injection of PD-134,308 into the anterior nucleus accumbens, the central amygdala or the caudate nucleus did not modify CSM. The antidepressant-like effects elicited by RB 101 in this test were potentiated by PD-134,308 after microinjection in the anterior nucleus accumbens and central amygdala, but not in the caudate nucleus. All these effects were observed only in shocked animals. The present results suggest that the mesolimbic system, particularly the anterior nucleus accumbens and the central amygdala, seems to play an important role in the interaction occurring between the endogenous CCK and opioid system in the control of behavioural responses.
Smadja
C
C
Département de Pharmacochimie Moléculaire et Structurale, INSERM U266, CNRS D 1500, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.
Ruiz
F
F
Coric
P
P
Fournié-Zaluski
M C
MC
Roques
B P
BP
Maldonado
R
R
D000679:Amygdala / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002421:Caudate Nucleus / Q000187:drug effects / Q000502:physiology; D004220:Disulfides / Q000494:pharmacology*; D004745:Enkephalins / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006727:Hormone Antagonists / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008032:Limbic System / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*
D004220:Disulfides; D004745:Enkephalins; D004791:Enzyme Inhibitors; D006727:Hormone Antagonists; D007211:Indoles; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C065599:PD 134308; C074024:RB 101; D010649:Phenylalanine; D008536:Meglumine; D015260:Neprilysin